Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy

We examined whether epidermal growth factor receptor (EGFR) expression in circulating tumor cells (CTCs) can be used to predict survival in a population of bone-metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel chemotherapy. All patients with mCRPC who had exper...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2016-12, Vol.17 (12), p.2008-2008
Main Authors: Okegawa, Takatsugu, Itaya, Naoshi, Hara, Hidehiko, Tambo, Mitsuhiro, Nutahara, Kikuo
Format: Article
Language:English
Subjects:
biomarker
Biomarkers
Biomarkers, Tumor - blood
Biomarkers, Tumor - metabolism
castration-resistant prostate cancer
Cellular biology
circulating tumor cells
Disease Progression
EGFR
Epidermal growth factor
Humans
Male
Neoplastic Cells, Circulating - metabolism
Neoplastic Cells, Circulating - pathology
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - blood
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - metabolism
Prostatic Neoplasms, Castration-Resistant - pathology
Receptor, Epidermal Growth Factor - blood
Taxoids - therapeutic use
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We examined whether epidermal growth factor receptor (EGFR) expression in circulating tumor cells (CTCs) can be used to predict survival in a population of bone-metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel chemotherapy. All patients with mCRPC who had experienced treatment failure with androgen-deprivation therapy and had received docetaxel chemotherapy were eligible. CTCs and EGFR expression in CTCs were enumerated with the CellSearch System in whole blood. This system is a semi-automated system that detects and enriches epithelial cells from whole blood using an EpCAM antibody-based immunomagnetic capture. In addition, the EGFR-positive CTCs were assessed using CellSearch Tumor Phenotyping Reagent EGFR. The median CTC count at baseline before starting trial treatment was eight CTCs per 7.5 mL of blood (range 0-184). There were 37 patients (61.7%) who had ≥5 CTCs, with median overall survival of 11.5 months compared with 20.0 months for 23 patients (38.3%) with
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms17122008